<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220315054298N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-27</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>effect of ketamine on controlling pain after total knee arthroplasty</public_title>
      <acronym></acronym>
      <scientific_title>comparison of the Effectiveness of pre-operative intravenous ketamine administration with placebo in controlling post-operative pain in patients with advanced knee osteoarthritis undergoing total knee arthroplasty</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62552</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: block randomization will be used to produce randomized sequences .each block will consists of 4 sites including 2 placebos(B) and 2 drugs(A).That way,6 randomization pattern(permutations of 2 from 4) will be available. Random choosing of the above mentioned sites will be performed based on www.randomization.org. and will be performed Hiddenly .
The placebo/drug that each patient receives will be concealed from the physician, statistician and the patient.   

30  concealed envelopes that contain instructions for mixing solutions for group A, and the other 30 for group B are put on each other.
content of each envelope is based on previously instructed randomization pattern.

After entering the patient to the operating room ,an anesthesiology technician  not involving in other part of the study will choose the first envelope from the top and follow the instructions of preparing the syringe content.

He then documents the patient's ID and  predetermined group.
thereafter, he does not partake in any subsequent part of the study .after data gathering and completion of the analysis,the A/B labels will be decoded to prepare the final manuscript.
None of the other investigators involved in patient management or data collection is aware of the group assignment, Blinding description: 60 identical sequentially numbered, opaque, sealed, and stapled envelopes(30 envelopes contain instructions for mixing solutions for group A, and the other 30 for group B) are put on each other.
content of each envelope is based on previously instructed block randomization pattern.

After entering the patient to the operating room ,an anesthesiology technician  not involving in other part of the study will choose the first envelope from the top and follow the instructions of preparing the syringe content. The volume of each syringes will  reaches 5 cc by adding normal saline so all of the injected syringes in A/B groups contains the same volume. Also, both ketamine and normal saline study solutions had the same physical properties: clear liquids with no distinctive odor .Therefore, they can not be identified or differentiated by sight or smell .

The technician then documents the patient's characteristics  and A/B intervention groups. The patient ,the surgeon and date collecting team members are blind of the injected liquid.
After data gathering and completion of the analysis the A/B labels will be decoded to prepare the final manuscript.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Osteoarthritis of knee.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 0.5 miligram per kilogram of body weight  ketamine in 5 cc syringe and increase to total volume of 5ml with normal saline. after spinal anesthesia and before incision, intravenously injected in 2 minutes. Intervention 2: Control group:  5 cc normal saline.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is data would be available on reasonable request from journal editor</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sina Javidmehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8490 1000</telephone>
        <email>sinajavidmehr@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sina Javidmehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital,Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8490 1000</telephone>
        <email>sinajavidmehr@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Between 18 and 85 years old
undergoing unilateral, primary total knee arthroplasty "TKA" for degenerative end-stage osteoarthritis(OA) of the knee (score of &gt;2 on Kellgren-Lawrence scale).</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>85 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patients who refuse to participate,
classified as ASA IV or V by the American Society of Anesthesiologists,
body mass index greater than 40 kg/m2,
rheumatoid arthritis,
contraindication or allergy to opioid pain medications
allergy to amide or sulpha anesthetics,
unable to understand the visual analog scale (VAS) ,
any preoperative ketamine or chronic narcotic usage (&gt;10mg systemic morphine equivalents daily ) as it causes opioids tolerance ,
those who are discharged before the first 24 hours postoperatively,
previous history of knee arthroplasty,
prior surgery on the ipsilateral knee within 6 months,
simultaneous bilateral arthroplasty,
the patients receiving general anesthesia or a nerve block
patients with an ejection fraction of less than 30%,
creatinine clearance of less than 30mL/min,
chronic liver disease,
any neurologic or psychiatric disorder (including bipolar,post-traumatic stress disorder, schizophrenia),
chronic alcohol abuse</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unilateral primary osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 0.5 miligram per kilogram of body weight  ketamine in 5 cc syringe and increase to total volume of 5ml with normal saline. after spinal anesthesia and before incision, intravenously injected in 2 minutes.</i_keyword>
      <i_keyword>Control group:  5 cc normal saline</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: 2 hour , 6hour , 12 hour ,24 hour ,10 days ,42 days post operative. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Maximum post op knee flexion. Timepoint: at discharge ,post op day 10 , post op day 42. Method of measurement: orthopedic ruler.</sec_outcome>
      <sec_outcome>Hospital stay duration. Timepoint: from the end of operation to discharge time. Method of measurement: time-hour.</sec_outcome>
      <sec_outcome>Time of first morphine request. Timepoint: from the end of operation to first time of morphine request. Method of measurement: time-hour.</sec_outcome>
      <sec_outcome>Total morphine(analgesics) consumption. Timepoint: at the time of discharge. Method of measurement: mg/kg....patient document.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-21</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Orthopedics ward, Shariati Hospital, Jalale ale ahmad Ave., Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
